Effects of Fluvastatin and Bezafibrate Combination on Plasma Fibrinogen, t-Plasminogen Activator Inhibitor and C Reactive Protein Levels in Coronary Artery Disease Patients with Mixed Hyperlipidaemia (FACT Study) – A Rebuttal

• References

• 1 Cortellaro M. et al. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Thromb Haemost 2000; 83: 549-53.
• 2 Ridker PM. et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-5.
• 3 Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease (letter). Lancet 1999; 353: 118-9.
• 4 Ridker PM. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
• 5 Tracy RP. et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-7.
• 6 Koenig W. et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
• 7 Ridker PM. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
• 8 Shine B, de Beer FC, Pepys MB. Solid phase radioimmunoassays for C-reactive protein. Clin Chim Acta 1981; 117: 13-23.
• 9 Pepys MB. The acute phase response and C-reactive protein, in Oxford Textbook of Medicine. Weatherall DJ, Ledingham JGG, Warrell DA. (editors) Oxford University Press; Oxford: 1996: 1527-33.